BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 23702347)

  • 1. [Anti-tumor necrosis factor-α medications and pregnancy].
    Simon PC; Vallano A
    Med Clin (Barc); 2013 Sep; 141(6):257-9. PubMed ID: 23702347
    [No Abstract]   [Full Text] [Related]  

  • 2. Potential use of TNF-α inhibitors in systemic sclerosis.
    Murdaca G; Spanò F; Contatore M; Guastalla A; Puppo F
    Immunotherapy; 2014; 6(3):283-9. PubMed ID: 24762073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IBD: Can TNF inhibitors be administered during the third trimester?
    Nielsen OH; Jess T
    Nat Rev Gastroenterol Hepatol; 2013 Mar; 10(3):130-1. PubMed ID: 23247511
    [No Abstract]   [Full Text] [Related]  

  • 4. Severe fungal infections linked to drugs.
    Kuehn BM
    JAMA; 2008 Oct; 300(14):1639. PubMed ID: 18840827
    [No Abstract]   [Full Text] [Related]  

  • 5. A PEGylated Fab' fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action.
    Bourne T; Fossati G; Nesbitt A
    BioDrugs; 2008; 22(5):331-7. PubMed ID: 18778114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of biologic agents in pregnancy and breastfeeding.
    Horst S; Kane S
    Gastroenterol Clin North Am; 2014 Sep; 43(3):495-508. PubMed ID: 25110255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents.
    Nesbitt A; Fossati G; Bergin M; Stephens P; Stephens S; Foulkes R; Brown D; Robinson M; Bourne T
    Inflamm Bowel Dis; 2007 Nov; 13(11):1323-32. PubMed ID: 17636564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti TNF-alpha treatment for Crohn' disease: "ménage a trois".
    Danese S
    Curr Drug Targets; 2010 Feb; 11(2):136-7. PubMed ID: 20214597
    [No Abstract]   [Full Text] [Related]  

  • 9. [Treatment of rheumatic diseases: current status and future prospective. Topics: III. Biological drugs; 1. TNF inhibitors].
    Amano K
    Nihon Naika Gakkai Zasshi; 2011 Oct; 100(10):2966-71. PubMed ID: 22175139
    [No Abstract]   [Full Text] [Related]  

  • 10. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists.
    Williams VL; Cohen PR
    Int J Dermatol; 2011 May; 50(5):619-25. PubMed ID: 21506984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor necrosis factor inhibitors in psoriasis: an update.
    Kerdel FA; Strober BE
    Semin Cutan Med Surg; 2014 Mar; 33(2 Suppl 2):S31-6. PubMed ID: 24979543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Biological therapies in rheumatology].
    Von Frenckell C; Malaise MG
    Rev Med Liege; 2009; 64(5-6):293-300. PubMed ID: 19642462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alopecia induced by tumour necrosis factor-alpha antagonists: description of 52 cases and disproportionality analysis in a nationwide pharmacovigilance database.
    Béné J; Moulis G; Auffret M; Lefevre G; Coquerelle P; Coupe P; Péré P; Gautier S
    Rheumatology (Oxford); 2014 Aug; 53(8):1465-9. PubMed ID: 24681837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis.
    Machado MA; Barbosa MM; Almeida AM; de Araújo VE; Kakehasi AM; Andrade EI; Cherchiglia ML; Acurcio Fde A
    Rheumatol Int; 2013 Sep; 33(9):2199-213. PubMed ID: 23686218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists.
    Mitoma H; Horiuchi T; Tsukamoto H; Ueda N
    Cytokine; 2018 Jan; 101():56-63. PubMed ID: 27567553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.
    Levy-Clarke G; Jabs DA; Read RW; Rosenbaum JT; Vitale A; Van Gelder RN
    Ophthalmology; 2014 Mar; 121(3):785-96.e3. PubMed ID: 24359625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased hospitalizations in elderly with inflammatory bowel disease on anti-tumor necrosis factor therapy but not increased infections: a community practice experience.
    Shen H; Lipka S; Katz S
    J Crohns Colitis; 2014 Aug; 8(8):898-9. PubMed ID: 24434182
    [No Abstract]   [Full Text] [Related]  

  • 18. Biological agents in monotherapy for the treatment of rheumatoid arthritis.
    Gabay C; Hasler P; Kyburz D; So A; Villiger P; von Kempis J; Walker U
    Swiss Med Wkly; 2014; 144():w13950. PubMed ID: 24723273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug insight: antagonists of tumor-necrosis factor-alpha in the treatment of inflammatory bowel disease.
    Chang JT; Lichtenstein GR
    Nat Clin Pract Gastroenterol Hepatol; 2006 Apr; 3(4):220-8. PubMed ID: 16582964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The classics in perspective.
    Panés J; Ghosh S
    Gut; 2007 Sep; 56(9):1184-6. PubMed ID: 17698863
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.